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Introduction
Sjögren-Larsson Syndrome (SLS) is an autosomal recessive
disease characterized by ichthyosis, neurological retardation,
spastic diplegia or tetraplegia, and a distinct retinopathy. It is
caused by mutations in the ALDH3A2 gene which result in
decreased activity of fatty aldehyde dehydrogenase (FALDH).
This enzyme is necessary for the conversion of aliphatic fatty
aldehydes into their fatty acid counterparts and plays a role in the
greater fatty alcohol oxidation complex.
One challenge in characterizing SLS is in estimating disease
incidence. The condition was first reported in 1957 in a Swedish
population at a high incidence likely due to consanguinity and
founder effects, but the scope of the disease globally has been
more difficult to determine. An estimated incidence of 1 in 250,000
is commonly cited but the accuracy of this estimate is uncertain.

One way to more accurately determine the incidence of SLS is by
tracking variations in the ALDH3A2 gene. Through genomic
sequencing, researchers have identified common pathogenic
variants in the gene, such as the c.943C>T variant which is
responsible for the largest subset of cases. There are also
several DNA databases that collect information on other variants
in the gene in control populations, but many of these variants
actually prove to be benign. Prediction programs such as
PROVEAN, PolyPhen-2, and SIFT all attempt to assess the
pathogenicity. However, these programs also have limited
accuracy. The best method to assess whether variants in
ALDH3A2 cause disease is to express the mutant proteins and
evaluate their effect on enzyme activity.

Methods

Results
Fig 1. Phenotypic
skin condition of
SLS.
Ichthyosis
present on upper
face, arms, and
chest.

Fig 3. Residual FALDH enzyme activity of 24 ALDH3A2 pathogenic
missense variants detected in SLS patients.
Data is expressed as a percent of wild-type enzyme activity. All but one of
the expressed patient-case variants had <15% activity when compared to
the wild-type. The c.798G>C variant demonstrated 55 percent activity but
has been reported to code for an unstable transcript.

Conclusions
Fig 2. Distribution of pathogenic variants in the ALDH3A2 gene found
in affected SLS patients and their predicted pathogenicity.
Missense mutations are the most common type pathologic variant in SLS
patients. Nonsense mutations are more common than frameshifts based
on reported data. The PROVEAN, SIFT, and PolyPhen-2 prediction
programs accurately determined 73% of the missense variants to be
pathogenic but did not assess the other 27% of disease-causing missense
variants to be pathogenic. (See Table 1)

➢ Based on ExAC and NHLBI database allele frequencies and
the PROVEAN, SIFT, PolyPhen-2 prediction programs,
estimated SLS incidence is between 1 in 320,000 and 1 in
450,000.

➢ The software prediction programs utilized can be helpful for
Fig 4. Residual FALDH enzyme activity of selected ALDH3A2 variants
that are predicted to be pathogenic based on prediction programs.
These variants were selected from DNA databases and predicted to be
pathogenic using the PROVEAN, SIFT, and PolyPhen-2 prediction
programs. Based on the expression data from confirmed disease-causing
variants (Fig 3), variants with <15% residual enzyme activity are expected to
be pathogenic.

programs in predicting pathogenicity by comparing their
assessments against previous expression data

➢ Express

missense variants predicted to be pathogenic and
determine whether the variants destroy FALDH function
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➢ Use ALDH3A2 variant allele frequencies provided by the ExAC
➢ Evaluate the accuracy of the PROVEAN, PolyPhen-2, and SIFT

identifying potential disease-causing variants but should not
be used alone to determine variants’ pathogenicity. The
programs appear to overestimate the damage caused by
single-nucleotide changes.
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and NHLBI databases and the Hardy-Weinberg equation to
estimate disease incidence

Single-site mutagenesis was conducted in a mammalian
expression vector containing the ALDH3A2 cDNA using a
QuikChange II Site-directed mutagenesis kit. Variants were
confirmed by sequencing. This DNA was transfected into
Chinese hamster ovary (CHO) cells using Lipofectamine.
FALDH enzyme activity in the CHO cells was measured one
day later and expressed as a percentage of activity seen in
wild-type ALDH3A2 vector.
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Table 1. Mutation types in ALDH3A2 variants known to be pathogenic.

ALDH3A2 Variants in SLS Patients
Missense
Inserts/Deletions/Frameshfits
Nonsense

55
26
43

Prediction Accuracy in SLS Missense Variants
Correctly predicted as pathogenic by all 3 programs 40
Not identified as pathogenic by all 3 programs
15

Table 2. ALDH3A2 variants identified in the ExAC and NHLBI databases
Types of Non-Synonymous Database Variants
Missense
295
Inserts/Deletions/Frameshifts
28
Nonsense
7
Intron/Splicing
319
Untranslated Region
41
Other
6
Total
696
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